Scientific Updates for Optimal Outcomes in Patients with Bladder Cancer


Program Dates: April 2, 2019 – April 1, 2020
Credits: 1.0 AMA PRA Category 1 Credit™; 1.0 CNE contact hour


Micrograph of Invasive urothelial carcinoma high grade. Invasive urothelial carcinoma is a type of Transitional cell carcinoma (TCC, also urothelial cell carcinoma or UCC) and is a type of cancer that develops in the urinary system: the kidney, urinary bladder, and accessory organs. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. Invasive urothelial carcinoma originates from tissue lining the inner surface of these hollow organs - transitional epithelium. It can extend from the kidney collecting system to the bladder. H&E Stain

Scientific Updates for Optimal Outcomes in Patients with Bladder Cancer

Program Overview

This CME/CNE activity will review recent advances in patients with Bladder Cancer as presented at the American Society of Clinical Oncology- Genitourinary Cancers (ASCO GU) 2019 Symposium in San Francisco, CA. Dr. Richard Lee will inform on clinical decision making for patients with bladder cancer by reviewing the science and tumor microenvironment. He will also discuss the latest clinical treatment options for the treatment of bladder cancer, and how to utilize evidence based management strategies to improve patient outcomes. Upon completion of this activity, learners will gain knowledge on how to implement emerging therapeutics of bladder cancer to treat patients and ultimately improve patient outcomes.

Target Audience

Oncologists, urologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with bladder cancer

Learning Objectives

1. Review the science and tumor microenvironment to inform clinical decision making for bladder cancer
2. Analyze the trial data of therapeutic latest clinical options for the treatment of bladder cancer
3. Apply evidence-based management strategies to improve outcomes in patients with bladder cancer

Faculty

 

Dr. Richard Lee HeadshotRichard JaeBong Lee, MD, PhD
Assistant Professor of Medicine
Harvard Medical School
Assistant Physician, Mass General Cancer Center

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

FacultyRelationship Identified With:
Richard JaeBong Lee, MD. PhDNothing to Disclose

 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Emma Boring and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hours). Provider number P0491.

Financial Support

This activity has been supported by independent educational grants from Incyte Global.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Incyte Global do not recommend the use of any agent outside of the labeled indications

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].

BUTTON

Provided by AcademicCME AcademicCME-web